Kallelse till årsstämma i Infant Bacterial Therapeutics
05 avr. 2022 14h00 HE
|
Infant Bacterial Therapeutics AB
Aktieägarna i Infant Bacterial Therapeutics AB (publ) kallas till årsstämma onsdagen den 4 maj 2022. Mot bakgrund av coronaviruset genomförs årsstämman genom förhandsröstning med stöd av tillfälliga...
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
05 avr. 2022 14h00 HE
|
Infant Bacterial Therapeutics AB
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted...
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
08 mars 2022 02h00 HE
|
VAXIMM AG
VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen fieldNEC OncoImmunity to initiate first clinical trial...
The Connection Study fortsätter efter planerad säkerhetsanalys av Data Monitoring Committee (DMC)
19 janv. 2022 17h30 HE
|
Infant Bacterial Therapeutics AB
Den 30 september, 2021 meddelade Infant Bacterial Therapeutics (IBT) att företaget nått en viktig milstolpe i utvecklingen av IBP-9414, efter att ha rekryterat 600 för tidigt födda barn till The...
The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
19 janv. 2022 17h30 HE
|
Infant Bacterial Therapeutics AB
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The...
Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Australien
10 janv. 2022 16h30 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att patentverket i Australien utfärdat ett godkännande för patentet: “A method of activating lactic acid bacteria”, vilket omfattar formuleringar...
Infant Bacterial Therapeutics today announces that new patent protection is granted in Australia
10 janv. 2022 16h30 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) today announces that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of...
Infant Bacterial Therapeutics tillkännager idag att nya patent har godkänts i Brasilien samt i Hong Kong
27 déc. 2021 16h30 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att patentverken i Brasilien och Hong Kong har godkänt ett patent för Lactobacillus reuteri som omfattar IBP-9414. IBP-9414 är den...
Infant Bacterial Therapeutics today announces new patent protection approvals in Brazil and in Hong Kong
27 déc. 2021 16h30 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB today announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its drug...
Infant Bacterial Therapeutics CFO lämnar bolaget
10 déc. 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs Chief Financial Officer (CFO) Marie Louise Alamaa har idag lämnat IBT för att anta nya utmaningar. IBTs Controller, Michael Owens, har samtidigt tillträtt som ny...